Sudershan Drugs And Intermediates Limited - Company Profile

It is a pharma public limited company based in Kanukunta Village, Telangana, India, established in 1982.
1982 Kanukunta Village, Telangana, India Active
Last Updated:
Access Report
About Sudershan Drugs And Intermediates Limited

Sudershan Drugs And Intermediates Limited, a active public limited company, was established on 30 December 1982 in Kanukunta Village, Telangana, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24230TG1982PLC003759. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹13.50 Cr and a paid-up capital of ₹13.50 Cr.

It upholds a compliant status. Its leadership includes Appala Charyulu Chilakanarri (Director), Subbaraju Gokaraju (Director), Yoganandavenkata Somayajulu Nuthi Subrahamanya (Managing Director). Past directors included Yoganandavenkata Somayajulu Nuthi Subrahamanya, Subbaraju Gokaraju, Gokaraju Ramaraju. It holds ₹53.00 Cr open charges and ₹11.00 Cr settled loans. Its latest AGM occurred on 26 September 2025, with the balance sheet filed on 31 March 2025. It is based at Kanukunta Jinnaram Mandal, Kanukunta Village, Telangana, 502313.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24230TG1982PLC003759

  • Registration Number

    003759

  • Incorporation Date

    30 December 1982

  • Authorized Capital

    ₹13.50 Cr

  • Paid-Up Capital

    ₹13.50 Cr

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 13.50 Cr
  • Paid Up Capital ₹ 13.50 Cr
  • Company Age 43 Year, 2 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 53.00 Cr
  • Satisfied Charges ₹ 11.00 Cr
  • Revenue Growth **** 0.77%
  • Profit Growth **** -8.95%
  • Ebitda **** -6.01%
  • Net Worth -7.26%
  • Total Assets -0.39%
Company report

Sudershan Drugs And Intermediates Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Sudershan Drugs And Intermediates Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Sudershan Drugs And Intermediates Limited?
Current Directors
Name Designation Appointment Date Status
Appala Charyulu Chilakanarri Director 15 May 2005 Current
Subbaraju Gokaraju Director 30 Sep 1994 Current
Yoganandavenkata Somayajulu Nuthi Subrahamanya Managing Director 22 Dec 2017 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Chief Financial Officer - Past
Pramod Abcsdd Managing Director 01 Sep 2020 Past
Pramod Abcsdd Director 20 Dec 2017 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Sudershan Drugs And Intermediates.

Sudershan Drugs And Intermediates Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.77% increase. The company also saw a slight decrease in profitability, with a 8.95% decrease in profit. The company's net worth dipped by a decrease of 7.26%.

Sudershan Drugs And Intermediates revenue growth over time
Sudershan Drugs And Intermediates profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 0.77%
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
 -0.39%
*******
*******
*******
*******
Profit or Loss
*******
 -8.95%
*******
*******
*******
*******
Net Worth
*******
 -7.26%
*******
*******
*******
*******
EBITDA
*******
 -6.01%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Sudershan Drugs And Intermediates?

In 2023, Sudershan Drugs And Intermediates had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹530,000,000.00

Satisfied Charges

₹110,000,000.00

Charges Breakdown by Lending Institutions
  • Gr Intrachem Ltd : 29.00 Cr
  • Canara Bank : 20.00 Cr
  • The Industrial Credit & Investment Corp. Of India Ltd : 3.50 Cr
  • State Bank Of India : 0.50 Cr
Latest Charge Details
Date Lender Amount Status
27 Dec 2000 Gr Intrachem Ltd ₹12.00 Cr Open
30 Mar 2000 Gr Intrachem Ltd ₹5.00 Cr Open
06 Dec 1997 Canara Bank ₹20.00 Cr Open
10 Mar 1995 Gr Intrachem Ltd ₹12.00 Cr Open
17 Jul 1993 State Bank Of India ₹5.00 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Sudershan Drugs And Intermediates?

Unlock and access historical data on people associated with Sudershan Drugs And Intermediates, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Sudershan Drugs And Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sudershan Drugs And Intermediates's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Sudershan Drugs And Intermediates
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Sudershan Drugs And Intermediates Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records. was documented.

  • Balance Sheet

    Progress on Sudershan Drugs And Intermediates Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.

  • Director Appointment

    Progress on Subbaraju Gokaraju was appointed as a CFO was appointed as a CFO on 01 Sep 2020 & has been associated with this company since 5 years 6 months . was documented.

  • Director Appointment

    Priya Khetan was appointed as a Company Secretary was appointed as a Company Secretary on 13 Jun 2019 & has been associated with this company since 6 years 9 months . was recorded as a recent event.

  • Director Appointment

    The activity Yoganandavenkata Somayajulu Nuthi Subrahamanya was appointed as a Managing Director was appointed as a Managing Director on 22 Dec 2017 & has been associated with this company since 8 years 2 months . was completed.

  • Charges

    A charge registered on 06 Mar 2000 via Charge ID 90124640 with The Banares State Bank Ltd was fully satisfied on 06 Dec 2008. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Sudershan Drugs And Intermediates Limited?

The CIN of Sudershan Drugs And Intermediates Limited is U24230TG1982PLC003759.

Where is Sudershan Drugs And Intermediates Limited headquartered?

Sudershan Drugs And Intermediates Limited is headquartered at Kanukunta Jinnaram Mandal, Kanukunta Village, Telangana, 502313.

When was Sudershan Drugs And Intermediates Limited incorporated?

Sudershan Drugs And Intermediates Limited was incorporated on 30 December 1982.

Who are the current directors of Sudershan Drugs And Intermediates Limited?

The current directors of Sudershan Drugs And Intermediates Limited are

What is the primary industry of Sudershan Drugs And Intermediates Limited?

The primary industry of Sudershan Drugs And Intermediates Limited is Pharma.

Is Sudershan Drugs And Intermediates Limited a listed company?

Sudershan Drugs And Intermediates Limited is unlisted.

What is the capital structure of Sudershan Drugs And Intermediates Limited?

The authorized capital of Sudershan Drugs And Intermediates Limited is ₹13.50 Cr, and the paid-up capital is ₹13.50 Cr.

What is the compliance status of Sudershan Drugs And Intermediates Limited?

The compliance status of Sudershan Drugs And Intermediates Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available